The hierarchical level of stem cell involvement in acute promyelocytic leukemia (APL) characterized by the pathognomonic PML-RARA fusion gene is unknown. To determine if the cells of the primitive hematopoietic stem cell compartment are involved in the leukemic process, we have used molecular and cell sorting techniques in peripheral blood and bone marrow (BM) cells at diagnosisfrom three patients with APL and t(15;17). In two of them, clonalii analysis was also possible using the BstXl polymorphic site of the PGK gene. The PML-RARA fusion gene was readily identified by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of BM cells obtained at diagnosis in all three patients. These same samples were then used t o sort CD34' cells and their CD38+ and CD38-subsets by fluorescenceactivated cell sorting. In both female patients, CD34'1CD38' and CD34+/CD38-cell fractions were polyclonal using PCR, whereas a monoclonal pattern was identified at the BM sample obtained at diagnosis either by Southern blotting or by PCR. Because of the high sensitivity of the PCR analysis, the polyclonal pattern of these cell populations could mask the presence of a minor clone. To detect this clone, we performed RT-PCR analysis for t(15;17). In one female patient, the abnormal PML-RAR fusion gene was found only in the CUTE PROMYELOCYTIC leukemia (APL) is characterized by a reciprocal 15; 17 translocation and a rearrangement of PML and RARA Although it has been assumed that the target cell for leukemic transformation had a committed phenotype, direct evidence documenting the absence of involvement of the primitive stem cell compartment by the leukemic process is lacking. Clonality analysis at the level cf hematopoietic progenitors in acute myelogenous leukemia (AML) has shown the heterogeneity of stem cell involvement in this disorder.3 The degree of stem cell involvement at the level of the primitive stem cells has not been studied extensively, mainly because of the lack of informative patients using glucose 6 phosphate dehydrogenase (G6PD) analysis. In a single APL patient studied by Fialkow et a13 using nonpurified cells, both types of enzymes (A and B) were found in platelets and red blood cells (RBCs) during The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with l8 U.S.C. section 1734 solely to indicate this fact. 0 1995 by The American Society of Hematology. .00/0 2154 more mature CD34+/CD38+ cell fraction using a nested PCR approach, whereas the polyclonal CD34'/CD38-fraction was PML-RARA negative. These findings were confirmed in a third patient with APL in whom the PML-RARA transcripts were absent in the CD34'/CD38-cell fraction. To study the clonality at the level of clonogenic progenitors, we used in one patient PGK analysis by PCR of individual burst-forming units-erythroid and colony-forming units-granulocyte-macrophage obtained from the CD34'/CD38-and CD34'/CD38+ cell populations at diagnosis and from the BM sample obtained during remission. The two highly purified cell populations gave rise t o morphologically normal colonies clonal for both the BstXl site containing (A) and the BsfXl site lacking (B) PGK allelles, indicating their polyclonal content, a pattern that was also found in clonogenic progenitors obtained at remission. These findings strongly suggest that the primitive hematopoietic stem cells as defined by the CD34+/ CD38-antigens are not involved by the neoplastic process in APL. These results may have important implications for autografting strategies of retinoic acidlchemotherapy-resistant or relapsed patients.
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active leukemia, but RBCs were not studied before transfusion. With regard to the hemopoietic progenitors, only colony-forming unit-granulocyte-macrophage (Cm-GM) growth was obtained and some of these progenitors were nonclonal. ' The development of molecular techniques based on Xchromosome inactivation mosaicism has allowed the clonal analysis of a large number of hematopoietic malignancies over the last few year^.^.^ Recently, reverse transcriptase polymerase chain reaction (RT-PCR) techniques have also been developed for the detection of the specific PML-RARA gene rea~~angement,~ allowing therefore the study of the residual disease after treatment. The combined PCR-PGK analysis and the RT-PCR for PML-RARA rearrangement therefore represents a powerful tool to study clonality in APL. We have recently studied highly purified hematopoietic stem cells obtained at diagnosis from three patients with APL, in two of whom clonality analysis was possible using the BstXI polymorphic site of the PGK gene. The data provided evidence that the most primitive hematopoietic stem cells (CD34+/CD38-) are not involved in the neoplastic process because they are PML-RARA negative and contain hematopoetic progenitors that obviously derive from a clone that is different from the leukemic clone. These results may have important clinical and biologic implications.
MATERIALS AND METHODS
Case reports. Three patients were included in this study. All blood and bone marrow (BM) samples were obtained through informed consent after institutional approval. Clinical and biologic characteristics of the patients are shown in Table I Fluorescence analysis and cell sorting were performed on a twolaser, air-cooled EPICS Elite cytometer (Coultronics). Cells were analyzed and sorted on the basis of their light scatter properties and fluorescence intensity, as published elsewhere.8 Briefly, a lymphoidblast gate, which normally contains all the hematopoietic progenitors, was drawn according to a low to moderate forward scatter (FS) and to a very low side scatter (SS). Within this gate, the proportion of CD34' CD38+ cells and CD34' CD38-cells was estimated by determining first the channel number at which the negative control and the test sample curves crossed each other. Leukemic cells, which represented more than 70% of the analyzed cells, appeared out of this progenitor gate and were immunophenotypically CD34-CD38'. Thus, a CD34'CD38-cell fraction, a CD34TD38' cell fraction, and a CD34-cell fraction, which contained leukemic cells, T cells, and presumably B cells, were sorted at 1,500 to 2,000 cells per second and collected in phosphate-buffered saline (PBS) containing 50% fetal calf serum (FCS). Under these conditions, the purity of sorted cells attained is greater than 96%.
Hematopoietic progenitor assay.
Progenitor assays for patient no. 1 were performed from unsorted and cell-sorted subpopulations using standard methylcellulose c~l t u r e .~.~ Briefly, cells were plated in 35-mm dishes (Greiner, Nurtingen, Germany) in 1.1 mL of Iscove's modified Dulbecco's medium (IMDM) containing 0.8% methylcellulose (Fluka, Buchs, Switzerland), 30% FCS, 1% bovine serum albumin (BSA), 100 pmol/L 2-mercaptoethanol (Sigma, St Louis, MO), 2 mmol/L glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, 3 U/mL recombinant human erythropoietin (rhEpo; Boehringer, Mannheim, Germany), 100 U/mL recombinant human interleukin-3 (rhIL-3), 100 U/mL rhIL-l (Genzyme, Boston, MA), 200 U/mL recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF Genetics Institute, Cambridge, MA), 100 U/mL rhIL-6 (a gift from Dr L. Aarden, Red Cross Hospital, Amsterdam, The Netherlands), 50 ng/mL rhG-CSF (RhBne-Poulenc, Antony, France), and 50 ng/mL recombinant human stem cell factor (rhSCF; Amgen, Thousand Oaks, CA).
Duplicate cultures were incubated in a humidified atmosphere containing 5% COz in air at 37°C. BMMNCs before sorting were plated at IO5 cells/dish and CD34+CD38-, CD34'CD38', and CD34-sorted fractions were plated at 5.5 x IOz, IO', and 3 x IO4 cells per dish, respectively. Burst-forming units-erythroid (BFU-E) and CFU-GM were counted between 16 and 18 days of culture. BFU-E were subdivided into primitive and mature subclasses according to their number of clusters. CFU-GM were subdivided into mature (<500 cells/colony) and primitive (>500 cells/colony) subclasses.
In all cell fractions, both BFU-E and CFU-GM colonies were individually plucked for further molecular analysis (see below).
DNA analyses. DNA was extracted from diagnosis and remission samples of patient no. 1 and diagnosis samples of patient no. 2 using standard procedures. For PGK analyses using the Southern blot technique, 10 to 15 pg of DNA was digested with Pst I and BstXI and then half of the sample was further digested with Hpa I1 using 20 U/pg of DNA. Samples were then electrophoresed, transferred to Nylon membranes, and hybridized to an 800-bp PGK probe (kindly provided by B. Vogelstein, Johns Hopkins University, Baltimore, MD).
PCR analysis from purified cell populations and from individual hemopoietic colonies was performed on crude cell lysates because of the limited number of cells analyzed. For sorted cell populations, we have used DNA from 660 to 2,000 cells for patient no. 1 and 550 to 4,800 for patient no. 2 that were lysed in ddHzO at 95°C for 5 minutes and then frozen immediately. For PCR-PGK analysis of individual colonies, the technique described by Gilliland et aI6 was used. Briefly, each individual CFU-GM or BFU-E was plucked from the methylcellulose dish into 20 pL ddH20 and then placed at 95°C for 5 minutes. In some later experiments, each colony was initially digested with proteinase K for 1 hour at 50°C to increase the access of HpuII to the crude cell lysate originating from the colony. These samples were either frozen at -20°C or processed immediately. Half of the crude cell lysate sample was digested with 10 U of Hpa I1 in a total volume of 20 pL for 1 hour and half was left undigested.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From PCR analysis was performed on both fractions using the external and internal PGK oligonucleotides as described." After two rounds of PCR, 20 pL of the amplified product was digested with 15 AGT GCA GCC AGA CCC AGT GCC and RARA internal antisense nucleotides 1676-1696 GAG GGA GGG CTG GGC ACT ATC) for a further 35 or 40 cycles using the same parameters. Fifteen microliters of amplified product was electrophoresed in a 2% agarose gel and the product was visualized with ethidium bromide.
Quantity and quality of RNA was assessed by amplification of p actin" or the porphobilinogen deaminase (PBGD)" transcripts of the same cDNA.
The sensitivity of PML and RAR oligonucleotides under these conditions was determined by dilution of patient samples in HL60 cells with subsequent extraction of RNA. When the reaction was started with 5 pL of cDNA and two rounds of 35 cycles of PCR using internal primers, the sensitivity was approximately IO-'. The latter could be increased consistently to IO" when the reaction was performed with I2 pL of cDNA followed by two rounds of 40 cycles of PCR. No increase in sensitivity was obtained by hybridization with an internal probe (data not shown).
RESULTS
furienr no. 1. Figure 1 shows the results of the clonality analysis performed on the diagnostic and remission marrow samples from patient no. 1. The BMMNC fraction analyzed from the diagnosis sample showed a typical monoclonal pattern with the disappearance of the 1.05-kb fragment in the sample digested with Hpu I1 (Fig I , sample 1, lane b) . When the same analysis was performed on the remission BM, a polyclonal pattern was identified with the reappearance of the 1.05-kb band, indicating the emergence of cells that did not belong to the leukemic clone (Fig I, sample 2, lane b) .
This analysis also allowed us to determine the genotype of the leukemic cell population that had apparently originated from a cell in which the PGK allele lacking the BstXI site was active (Fig I , sample 1, lane b) .
After staining with CD38-FITC and CD38-PE MoAbs, this same diagnosis marrow sample was sorted by flow cytometry into three separate fractions as described in the Materials and Methods. CD34'CD38' cells and CD34TD38-cells represented 3.25% and 0.8% of the cells analyzed, respectively. Half of the sorted cell population was used for clonogenic assays, whereas the remaining half was used for DNA and RNA analyses. Table 2 shows the clonogenic potential of each purified cell populations scored at day 16 of the culture. Very few colonies were obtained from the starting cell sample and none were obtained from the CD34-cell fraction, whereas both granulocytic and erythroid colonies with a normal morphology were obtained from the purified CD34TD38' and CD34'CD38-cells. Individual hematopoietic colonies from these dishes were then plucked and stored at -20°C for PCRPGK analysis.
Both purified fractions (CD34+/CD38' and CD34+/ CD38-) were then used for PCRPGK analyses and for detection of PML-RAR rearrangement by RT-PCR. DNA analysis of both fractions showed a polyclonal pattern (Fig 2) .
A small difference could be shown between the CD34+/ CD38-and CD34'/CD38+ fractions in terms of 530/433 band ratios, but this was most likely caused by the occurrence of heteroduplexes favoring the amplification of the 530-bp band. Indeed, the comparison of lanes a and b in both fractions did not show any difference of band intensity and it is very likely that both cell populations had a polyclonal cell content (Fig 2) . Similarly, the CD34-fraction seemed also to have a polyclonal content, but we could show a clear shift towards the lower molecular weight 433-bp band in the presence of the methylation-sensitive enzyme. This finding is therefore consistent with the presence of a predominant population of cells that are clonal for the allele containing the BstXI site as suggested by the results of the Southern blot data at diagnosis (Fig 1) . This fraction contained essentially leukemic cells but also CD34-cells in the progenitor window, including T and B cells. The persistence of the upper band is probably caused by the presence of polyclonally derived T cells in the presence of heteroduplexes favoring the amplification of the 530-bp band (Fig   2) .
The fluorescence-activated cell sorter (FAG)-purified samples as well as the unsorted diagnostic BMMNC sample were then analyzed for the presence of a PML-RARA rearrangement using an RT-PCR technique. Initial nonnested RT-PCR analysis of diagnostic RNA using two sets of PML primers flanking the 5' and the 3' breakpoints in the PML gene showed a typical 3' breakpoint corresponding to bcr 1 of Lo Coco et all4 (data not shown). Further analyses were therefore performed with the bcr-l 3"specific primers. As shown in Fig 3, RT-PCR analysis using two rounds of 35 cycles of PCR and nested primers close to the PML-RAR junction allowed identification of the abnormal transcript in the leukemic monoclonal sample (Fig 3, lane 4) . To determine the sensitivity of our technique, we then performed dilution analysis of leukemic cells in HL60 cells. This allowed us to determine that, under the conditions used, l cell in 10' could be detected (Fig 3, lanes 5 through 8) .
The RNA analysis from the FACS-purified fractions was initially performed using 35 cycles of PCR after cDNA synthesis, followed by an additional 35 cycles using internal primers. This analysis showed both CD34'/CD38' and CD34'/CD38-fractions to be free of PML-RAR transcripts, whereas the actin transcript was readily identified (data not shown). To increase the sensitivity of our technique, we then increased the starting cDNA material from 5 pL to 12 pL and performed 2 rounds of 40 cycles of PCR under the same conditions. Using this approach, PML-RARA transcripts were detected in the CD34'/CD38+ cell fraction (Fig 3, lane  1 l) , whereas CD34'/CD38-cell fraction remained PML-RARA negative (Fig 3, lane IO) . Interestingly, using the same RT-PCR conditions, the unfractionated remission sample remained positive for PML-RARA transcripts (data not shown).
To determine the clonogenic content of the purified cell populations, we then used PCR-PGK analysis. Using this technique, which was first developed by Gilliland et al," each colony should give a typical clonal pattern with the disappearance of either the 530-bp or the 433-bp PGK allele in the H p 11-digested fraction because Hpa 11-digested fragments will not be amplified during PCR. Table 3 shows the results obtained with cell populations at diagnosis as well as the BM sample obtained during remission. These data indicate that both CD34'1CD38' and CD34+/CD38-cell populations contain colonies of both genotypes, ie, either with the 530-bp or the 433-bp PGK allele remaining active. More importantly, even in the CD34+/CD38' cell population in which RT-PCR analysis showed the presence of PML-RARA transcripts, we were able to identify colonies with a genotype opposite to that found in the leukemic promyelocytes (Table 3) . Similarly, the remission sample contained a normal distribution of colonies of both genotypes, with either the 530-bp or the 433-bp allele of PGK remaining active (Table 3 and Fig 4) .
Patient no. 2. Clonality analysis was performed on diagnosis BM sample and from the FACS-purified CD34'/ CD38' and CD34'/CD38-fractions. As shown in Fig 5 , PCR-PGK analysis of the BMMNC sample containing 92% of blasts showed a clonal pattern with the successful ampli- RT-PCR analysis of RNA from diagnosis and remission samples as well as from the FA=-purified cell populations in patient no. 1. RNA was extracted using guanidium isothiocyanate-acid phenol procedure, reverse-transcribed, and amplified with actin primers (internal control for the integrity of RNA) or primers specific for 3'PML breakpoint and RAR. Two rounds of 40 cycles of amplification were performed using internal primers. Lane l , size marker; lane 2, RNA from HL-60 cells (negative control); lane 3, water control; lane 4, blast cells at diagnosis, giving rise t o a 270-bp PML-RAR fragment; lanes 5 through 8, PML-RAR-positive diagnostic sample diluted in HL-60 cells before being processed for RNA extraction and PCR at lo", 10.'. lo-', and lo" dilutions, respectively; lane 9, BM sample before cell sorting; lanes 10, 11, and 12, RNA from CD34+/CD38-, CD34+/CD38', and CD34' fractions, respectively. Leukemia-specific PML-RAR fusion gene was not found in the CD34'1 CD38-cell population after two rounds of PCR of 35 cycles each and nested primers.
fication of 530-bp band in the Hpn 11-digested sample, contions, a polyclonal pattern was identified in both, with a sistent with the presence of a clonal amplification arising reduction of the Hpn I1 resistance of the 530-bp fragment, from a clone in which the PGK allele lacking the BstXI site indicating an enrichment of both cell populations on polywas active (Fig 5) . This finding was probably not caused by clonal progenitors. Clonal analysis at the level of clonogenic a skewed lyonization event because when the same analysis progenitors could not be performed and no RNA could be was performed in CD34+/CD38' and CD34+/CD38-fracobtained from the two purified CD34' subpopulations. The results shown represent the number of colonies successfully amplified and considered to be interpretable given the fact that technical artefacts (plucking fibroblasts or more than 1 colony) can give ambiguous results, as previously described. ' Colonies designated as type A are the progenitors that originated from a cell in which the PGK allele lacking the BstXl site remained active (similar to the pattern seen in Southern blot analysis of blast cells), as opposed to colonies type B with the PGK allele possessing the BstXl site remained active. Parien? no. 3. BM cells obtained at diagnosis (94% blast cells) were sorted into CD34'/CD38' and CD34'/CD38-fractions. RNA was extracted from the purified cells and RT-PCR was performed as described in the Materials and Methods. The integrity of the RNA obtained was checked with the amplification of these same cDNA with the PBGD primers.I3 Figure 6 shows the results of this experiment. The 270-bp PML-RARA fragment was amplified from the cells prior to cell sorting (Fig 6, upper . whereas the CD34'/ CD38-cell fraction remained PML-RARA negative (Fig 6,  upper panel, lane 3) despite the fact that the intensity of the PBGD band obtained from the CD34'/CD38-fraction was superior to that obtained from the blast-enriched CD34-fraction (Fig 6, lower panel, lane 3) . Finally, the intensity of the PBGD band in the CD34'/CD38' fraction was significantly superior to that obtained from the CD34-fraction (and almost equal to the unpurified BMMNCs), yet the 270-bp PML-RARA could barely be seen (Fig 6, upper panel, lane  2) .
DISCUSSION
The determination of target cell populations for neoplastic involvement is of considerable interest in AML as a specific translocation could occur preferentially in a certain stage of hematopoietic differentiation. In this report, we have studied three patients with APL using cell purification and molecular biology techniques. Our findings are consistent with the hypothesis that the target cell for neoplastic amplification in APL has a CD34+/CD38' phenotype. In two patients, clonal analysis could be performed using methylation analysis of BstXI polymorphic fragments of the PGK gene; in a third patient, who was a male, only an RNA-based PCR analysis could be performed from the purified CD34'/CD38' and CD34'/CD38-cell populations. In the first patient, in whom clonal analysis could be performed at the level of hematopoietic progenitors, we were able to show that both CD34'/ CD38' and CD34+/CD38-cell populations contained nonclonal progenitors, but the PML-RARA transcript was shown only in the CD34'/CD38' fraction. The latter finding could also be shown in the patient no. 3, with the presence of a faint band in the CD34'/CD38' fraction, whereas the CD34'/CD38-fraction was PML-RARA negative. This finding could be explained either by the selection of a small number of leukemic cells during the cell sorting process or, conversely, by the fact that some leukemic cells have the CD34'/CD38' phenotype. We are not able to distinguish at this time between these two possibilities. Our immunophenotyping data indicate that the leukemic cells obtained at diagnosis are essentially CD34-/CD38'. The presence of nonclonal progenitors in the PML-RARA-negative CD34'/ CD38-cell fraction as well as in the PML-RARA-positive CD34+/CD38' fraction from patient no.
at diagnosis
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From strongly suggests that the primitive hematopoietic stem cell compartment (CD34+/CD38-) is free of leukemic cells in APL. Although clonal analysis at the level of hematopoietic progenitors could not be performed in patients no. 2 and 3, FACS-purified CD34+/CD38-cell populations were either enriched on polyclonal progenitors (patient no. 2) or PML-RARA negative (patient no. 3) compared with unpurified BMMNCs or with blast-enriched CD34-cell populations (patient no. 3). One other possibility to explain the absence of PML-RARA transcripts in the CD34+/CD38-cell fraction could be the absence of transcription of PML-RARA gene in this particular subset of progenitors despite the presence of the t (15; 17) , a situation that has been recently described in some patients with CML." The methodology used in our study cannot address this possibility, which has never been described in APL. One reason that makes it unlikely is the nonclonal nature of FACS-purified CD34+/CD38-cells in two of the three patients that have been analyzed in this study. In both patients no. 1 and 2, BMMNCs obtained at diagnosis showed a clear clonal pattern that was different from the pattern found in CD34+/CD38-fractions. Moreover, in patient no. l , we have shown that 50% of informative clonogenic progenitors originating from the CD34+/CD38-fraction were of type B, which is different from the type A pattern found in the leukemic cells. However, a minor fraction of CD34+/CD38-cells could have a t(1.5; 17) without transcription of the PML-RARA hybrid gene and without detectable clonal amplification. This finding would then imply either the absence of self-renewal capacity in these cells that represent the most primitive hematopoietic stem cell fraction described in humans in terms of long-term culture initiation potentialI6 or the Occurrence of clonal amplification only during hematopoietic differentiation towards a CD34+/ CD38+ phenotype. Until the demonstration of the absence of transcription of a PML-RARA hybrid gene in CD34+/ CD38-cell populations in APL, these assumptions remain essentially hypothetical. A recent report using SCID mouse reconstitution model has shown the feasibility of an in vivo assay for stem cells initiating AML" with the demonstration, in a single patient with an FAB M1 subtype, of the origin of the leukemia in the CD34+CD38-fraction. Clearly, the use of both clonality and SCID mouse reconstitution experiments in other subtypes of AML at the level of hematopoietic stem cells could be extremely useful in the future. The results obtained with the single AML M1 patient in SCID model, compared with those obtained by X-chromosome inactivation analysis data: highlight the heterogeneity in AML at the level of stem cell involvement. As opposed to other subtypes of AML, APL has been characterized as a distinct entity with typical moleculari8 and clinical" features, including the unique in vitro and in vivo differentiative capacity with ATRA." The ability to distinguish primitive stem cells with nonneoplastic characteristics in APL has important research implications, especially in studying PML-RARA-associated leukemogenesis. Our results could also have important clinical implications. It is generally accepted that 20% to 30% of patients with APL will become resistant to ATRA and will eventually relapse. If the most primitive hematopoietic stem cell compartment is not involved, this would suggest that the employment of autografting strategies using purified CD34+ cell populations may be valid in APL. The use of CD34+ cell subpopulations for grafting are also being evaluated in some experimental settings.2' Finally, the CD34+/CD38-cell population in APL could be used for stem cell amplification or genetic manipulation purposes, when these techniques become available, in relapsed patients.
